A Study of KC1036 in Patients with Advanced Solid Tumors

Summary

The purpose of this study is to evaluate the safety，tolerability, pharmacokinetics, and preliminary efficacy of KC1036 in participants with advanced recurrent or metastatic solid tumors. The trial will be divided into three parts: dose-escalation phase, dose-expansion phase, RP2D-extension phase.

Timeline

Start

2020-09-04

Primary completion

2025-10-31

Completion

2025-12-31

Drugs

Indications